WO2003000232A3 - Procede de preparation de vesicules chargees d'oligodeoxynucleotides immunostimulateurs (iss-odn) et utilisations diverses de celles-ci - Google Patents

Procede de preparation de vesicules chargees d'oligodeoxynucleotides immunostimulateurs (iss-odn) et utilisations diverses de celles-ci Download PDF

Info

Publication number
WO2003000232A3
WO2003000232A3 PCT/IL2002/000507 IL0200507W WO03000232A3 WO 2003000232 A3 WO2003000232 A3 WO 2003000232A3 IL 0200507 W IL0200507 W IL 0200507W WO 03000232 A3 WO03000232 A3 WO 03000232A3
Authority
WO
WIPO (PCT)
Prior art keywords
odn
iss
liposomes
immunostimulator
oligodeoxynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2002/000507
Other languages
English (en)
Other versions
WO2003000232A2 (fr
Inventor
Yechezkel Barenholz
Eliezer Kedar
Yigal Louria-Hayon
Aviva Joseph
Eyal Raz
Kenji Takabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, University of California Berkeley, University of California San Diego UCSD filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Priority to AU2002311617A priority Critical patent/AU2002311617A1/en
Publication of WO2003000232A2 publication Critical patent/WO2003000232A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003000232A3 publication Critical patent/WO2003000232A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé simple et rapide permettant le piégeage efficace d'un ISS-ODN actif dans des liposomes, avec plus de 60 % de charge). Le procédé décrit dans cette invention consiste à sécher une suspension d'un matériau amphipathique, puis, à hydrater cette suspension avec une solution aqueuse contenant l'ISS-ODN, en piégeant ce dernier dans des liposomes formés à partir du lipide. Cette invention concerne un procédé efficace permettant de charger et de retenir l'ISS-ODN dans des vésicules liposomales. Des animaux traités avec l'ISS-ODN liposomale présentent un rythme de développement de la maladie plus lent par rapport à un ISS-ODN libre ou à des liposomes chargés avec un ISS-ODN mutant (lip M-ODN).
PCT/IL2002/000507 2001-06-25 2002-06-25 Procede de preparation de vesicules chargees d'oligodeoxynucleotides immunostimulateurs (iss-odn) et utilisations diverses de celles-ci Ceased WO2003000232A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002311617A AU2002311617A1 (en) 2001-06-25 2002-06-25 Method for preparation of vesicles loaded with immunostimulatory oligodeoxynucleotides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30007201P 2001-06-25 2001-06-25
US60/300,072 2001-06-25
US33978501P 2001-12-17 2001-12-17
US60/339,785 2001-12-17

Publications (2)

Publication Number Publication Date
WO2003000232A2 WO2003000232A2 (fr) 2003-01-03
WO2003000232A3 true WO2003000232A3 (fr) 2004-02-26

Family

ID=26971572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000507 Ceased WO2003000232A2 (fr) 2001-06-25 2002-06-25 Procede de preparation de vesicules chargees d'oligodeoxynucleotides immunostimulateurs (iss-odn) et utilisations diverses de celles-ci

Country Status (2)

Country Link
AU (1) AU2002311617A1 (fr)
WO (1) WO2003000232A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
CA2502015A1 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
EP1610763A2 (fr) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ensembles de lipides contenant des amphiphiles de formation non liposomique
KR20060015534A (ko) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
WO2007049279A2 (fr) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combinaison de liposomes et utilisations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172007A2 (fr) * 1984-08-10 1986-02-19 Syntex (U.S.A.) Inc. Liposomes stables à médicaments hydrosolubles
GB2164624A (en) * 1984-09-21 1986-03-26 Shionogi & Co Process for preparing liposome compositions
WO1999022772A1 (fr) * 1997-10-31 1999-05-14 Isis Pharmaceuticals, Inc. COMPOSITIONS LIPOSOMALES CONTENANT DES OLIGONUCLEOTIDES ET DESTINEES A MODULER L'EXPRESSION DU GENE ras
WO2000045849A2 (fr) * 1999-02-05 2000-08-10 Genzyme Corporation Utilisation de lipides cationiques pour generer une immunite anti-tumorale
WO2001015726A2 (fr) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions stimulant la secretion de cytokine et provoquant une reaction immunitaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172007A2 (fr) * 1984-08-10 1986-02-19 Syntex (U.S.A.) Inc. Liposomes stables à médicaments hydrosolubles
GB2164624A (en) * 1984-09-21 1986-03-26 Shionogi & Co Process for preparing liposome compositions
WO1999022772A1 (fr) * 1997-10-31 1999-05-14 Isis Pharmaceuticals, Inc. COMPOSITIONS LIPOSOMALES CONTENANT DES OLIGONUCLEOTIDES ET DESTINEES A MODULER L'EXPRESSION DU GENE ras
WO2000045849A2 (fr) * 1999-02-05 2000-08-10 Genzyme Corporation Utilisation de lipides cationiques pour generer une immunite anti-tumorale
WO2001015726A2 (fr) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions stimulant la secretion de cytokine et provoquant une reaction immunitaire

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GURSEL I ET AL: "Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.", JOURNAL OF IMMUNOLOGY, vol. 167, no. 6, 15 September 2001 (2001-09-15), pages 3324 - 3328, XP002228991, ISSN: 0022-1767 *
GÜRSEL M ET AL: "Immunoadjuvant action of plasmid DNA in liposomes.", VACCINE, vol. 17, no. 11-12, March 1999 (1999-03-01), pages 1376 - 1383, XP004158265, ISSN: 0264-410X *
LI WM ET AL: "Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.", VACCINE, vol. 20, no. 1-2, 12 October 2001 (2001-10-12), pages 148 - 157, XP004305127, ISSN: 0264-410X *
LUDEWIG B ET AL: "In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity.", VACCINE, vol. 19, no. 1, 15 August 2000 (2000-08-15), pages 23 - 32, XP004228807, ISSN: 0264-410X *
MCCLUSKIE MJ ET AL.: "The potential of CpG oligodeoxynucleotides as mucosal adjuvants", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 21, no. 1-3, 2001, ISSN: 1040-8401, pages 103 - 120, XP008012997 *
MUI B ET AL: "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 298, no. 3, September 2001 (2001-09-01), pages 1185 - 1192, XP002228992, ISSN: 0022-3565 *
SONEHARA K ET AL: "Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon.", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 16, no. 10, 1996, pages 799 - 803, XP000863569, ISSN: 1079-9907 *

Also Published As

Publication number Publication date
AU2002311617A1 (en) 2003-01-08
WO2003000232A2 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
CA2213151A1 (fr) Methode pour stabiliser des preparations pharmaceutiques renfermant des melanges d'enzymes digestives
CA2252055A1 (fr) Liposomes entrainant une fusion
EP2292771A3 (fr) Thérapie à base d'ARNm sens
IS4675A (is) Örþeytur til að nota sem burðarefni við inngjöf virkra efna
EP2258846A3 (fr) Procédé d'amélioration de la concentration d'une molécule d'acide nucléique
IL134703A0 (en) Process for controlling the loading of a biologically active agent into a liposome
AR001015A1 (es) Un procedimiento para preparar un poliester basado en 1,3-propanodiol
CA2296244A1 (fr) Adjuvants pour vaccins
IL117990A (en) Emulsion suitable for administering a poorly water-soluble photosensitizing compound and use thereof
ES2088160T3 (es) Formulacion y proceso quimicos.
WO1997030024A3 (fr) Composes lipidiques et leur utilisation, par exemple, dans des liposomes
CA2305704A1 (fr) Formation d'un complexe peptides/lipides par co-lyophilisation
ATE172636T1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
ES2088385T3 (es) Formulaciones de liposomas con una elevada relacion agente antineoplasico/lipido.
WO2003000233A3 (fr) Liberation de petites molecules hydrophiles comprises dans des vesicules lipidiques
WO2003000232A3 (fr) Procede de preparation de vesicules chargees d'oligodeoxynucleotides immunostimulateurs (iss-odn) et utilisations diverses de celles-ci
JP2001515852A5 (fr)
DE60028152D1 (de) Fester, stabiler und konzentrierter biologisch verdaulicher Komplex von Orthokieselsäure und Prozess zur dessen Herstellung
MXPA02005165A (es) Forma pulverizada de acido [(s)- 2-etoxi -3-[4 -(2-[4- metansulfoniloxifenil) etoxi)fenil ]propanoico].
ATE459340T1 (de) Zielgerichtete liposomen zur verabreichung von genen
MXPA02009797A (es) Preparaciones farmaceuticas y su manufactura.
EP0800822A3 (fr) Méthode de préparation de vésicules closes par réhydratation de vésicules déshydratées
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
CA2224565A1 (fr) Agent pour combattre les parasites en pisciculture
ZA966111B (en) Improving the tolerability of pharmaceutically active β-amino acids.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP